ABS-201 record · updated 4h ago

Grade C · preclinicalResearch use only

All 1 studies Jump to the evidence Compare

What is ABS-201 used for?

ABS-201 is an investigational IgG1 monoclonal antibody that targets the prolactin receptor (PRLR). It is a biologic rather than a peptide, and it appears in this library because it is in clinical development for androgenetic alopecia. Absci is testing it in a first-in-human Phase 1/2a trial that began dosing in December 2025 and is currently recruiting; the trial's primary endpoint is safety, not hair growth. No peer-reviewed study of ABS-201 in humans or animals has been published. It is not an approved medicine and cannot be prescribed or purchased.

How it works: IgG1 monoclonal antibody targeting the prolactin receptor (PRLR), blocking prolactin signalling.

Route · Intravenous for single ascending doses and subcutaneous for multiple ascending doses in the Phase 1/2a trial. No established clinical route.

Development stage

where ABS-201 sits between preclinical work and regulatory approval

1Current
Preclinical
Animal / in-vitro work
2Not reached
Phase 1
Safety in humans
3Not reached
Phase 2
Efficacy signal
4Not reached
Phase 3
Confirmatory trials
5Not reached
Approved
Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 1 registered trial. It describes the research record, not a recommendation.

Identity

NameABS-201

Full name—

Sequence—

ClassAesthetic

Research levelEmerging

Discovered byManually admitted · biologic, not a peptide · 2026

Pharmacology

MechanismIgG1 monoclonal antibody targeting the prolactin receptor (PRLR), blocking prolactin signalling.

RouteIntravenous for single ascending doses and subcutaneous for multiple ascending doses in the Phase 1/2a trial. No established clinical route.

Half-lifeEstimated at least 65 days per sponsor-reported interim Phase 1 data. Not peer reviewed.

Time to peak—

Duration—

Extraction confidence—

Effect profile · 0–5

These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. How this works →

Research stats

Total studies1

Human / animal / cellular0 / 0 / 0

Highest trial phase—

Years covered2026

Latest study4h ago

Publication history

20262026

Research funding

—no NIH grants found

Safety signals

FAERS reportsnone recorded

Serious AEs in animal work—

Community reports—

Positive —Neutral —Negative —

Records

PubChem PubMed · 1 Google Scholar Semantic Scholar ClinicalTrials.gov · 1

Study register

1 rowOpen in the library →

Study	Type	Year	Summary depth
Emerging pharmacotherapies for androgenetic alopecia. TakeawayConfirms ABS-201 is in clinical development for androgenetic alopecia as a prolactin-receptor-targeting biologic. It contains no data on whether it works.	review	2026	Partial text0.60